Journal of Hepatology
Volume 51, Issue 4 , Pages 626-627 , October 2009

Forewarned is forearmed

  • Stefan Zeuzem

      Affiliations

    • Corresponding Author InformationTel.: +49 (0)69 63014544; fax: +49 (0)69 63016448.

References 

  1. Seeff LB. The natural history of chronic hepatitis C virus infection. Clin Liver Dis. 1997;1:587–602
  2. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med. 2001;345:41–52
  3. Zeuzem S, Teuber G, Lee JH, Rüster B, Roth WK. Risk factors for the transmission of hepatitis C. J Hepatol. 1996;24:S3–S10
  4. Bochud P-Y, Cai T, Overbeck K, Bochud M, Dufour J-F, Müllhaupt B, et al. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J Hepatol. 2009;51:655–666
  5. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997;349:825–832
  6. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology. 2001;33:1358–1364
  7. Andriulli A, Mangia A, Iacobellis A, Ippolito A, Leandro G, Zeuzem S. Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis. Aliment Pharmacol Ther. 2008;28:397–404
  8. Hadziyannis SJ, Sette H, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346–355
  9. Shiffman ML, Suter F, Bacon BR, Nelson D, Harley H, Solá R, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med. 2007;357:124–134
  10. Zeuzem S, Hultcrantz R, Bourliere M, Goeser T, Marcellin P, Sanchez-Tapias J, et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol. 2004;40:993–999Erratum in: J Hepatol 2005;42:434
  11. Willems B, Hadziyannis SJ, Morgan TR, Diago M, Marcellin P, Bernstein D, et al. Should treatment with peginterferon plus ribavirin be intensified in patients with HCV genotype 2/3 without a rapid virologic response?. J Hepatol. 2007;46:S6
  12. McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med. 2009;360:1827–1838
  13. Hézode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med. 2009;360:1839–1850
  14. Kwo P, Lawitz E, McCone J, Schiff E, Vierling J, Pound D, et al. HCV Sprint-1 final results: SVR 24 from a phase 2 study of boceprevir plus PegIntronTM (peginterferon alfa-2b)/ribavirin in treatment-naive subjects with genotype-1 chronic hepatitis C. J Hepatol. 2009;50:S4
  15. Foster GR, Hezode C, Bronowicki J-P, Carosi G, Weiland O, Verlinden L, et al. Activity of telaprevir alone or in combination with peginterferon alfa-2a and ribavirin in treatment-naive genotype 2 and 3 hepatitis-C patients: interim results of study C209. J Hepatol. 2009;50:S22
  16. Benhamou Y, Moussalli J, Ratziu V, Lebray P, Gysen V, de Backer K, et al. Results of a proof of concept study (C210) of telaprevir monotherapy and in combination with peginterferon alfa-2a and ribavirin in treatment naive genotype 4 HCV patients. J Hepatol. 2009;50:S6
  17. Soriano V, Peters MG, Zeuzem S. New therapies for hepatitis C virus infection. Clin Infect Dis. 2009;48:313–320
  18. Gane EJ, Rodriguez-Torres M, Nelson DR, Jacobson IM, McHutchison JG, Jeffers L, et al. Antiviral activity of the HCV nucleoside polymerase inhibitor R7128 in HCV genotype 2 and 3 prior non-responders: interim results of R7128 1500mg bid with PEG-IFN and ribavirin for 28 days. Hepatology. 2008;48:1024A
  19. Flisiak R, Feinman SV, Jablkowski M, Horban A, Kryczka W, Pawlowska M, et al. The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naı¨ve hepatitis C patients. Hepatology. 2009;49:1460–1468

☆ The author declared that he does not have anything to disclose regarding funding or conflict of interest with respect to this manuscript.

PII: S0168-8278(09)00452-8

doi: 10.1016/j.jhep.2009.06.010

Journal of Hepatology
Volume 51, Issue 4 , Pages 626-627 , October 2009

Article Tools